Evidence map›Paper›PMID 41769292›Full record

ReviewArchives of Razi Institute2025

Next-Generation Vaccines and Antiviral Platforms: Molecular Advancements in the Struggle against Emerging Zoonotic and Viral Diseases.

Ebadi Abdol Ghaffar, Selamoglu Zeliha, Issa Hamdia Yousif, Alp Arici Elifsena Canan, Abbas Shahid

Abstract readReview
In one paragraph

Review in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ebadi Abdol GhaffarDepartment of Agriculture, Jo.C, Islamic Azad University, Jouybar, Iran.
Selamoglu ZelihaDepartment of Medical Biology, Medicine Faculty, Nigde Omer Halisdemir University, Nigde, Turkey.
Issa Hamdia YousifDepartment of Biology, College of Science, University of Zakho, Duhok, Iraq.
Alp Arici Elifsena CananDepartment of Obstetrics and Gynecology, Batman Training and Research Hospital, Batman, Turkey.
Abbas ShahidAllergy and Asthma Center, Blue Area, Islamabad, Pakistan. Former Chief, Clinical and Tropical Diseases Research Division, National Institute of Health, Islamabad. Former HOD Allergy & Immunology, NIH, Islamabad, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing occurrence of zoonotic and viral diseases, such as SARS-CoV-2, H5N1, Nipah, and Ebola viruses, underscores the requirement for transformative innovations in vaccine and antiviral development. Classic vaccine technologies like inactivated or live-attenuated virus products have lengthy production cycles, cold-chain storage, and are poorly suited to reacting rapidly to emerging threats This review synthesizes the most recent advances in molecular virology, immunogen design, and biotechnology that will propel the next generation of prevention and treatment tools. We begin with the genomic and structural characteristics of high-consequence zoonotic viruses, highlighting the molecular determinants for virulence, host switching, and immune evasion. The review then provides a comparative review of the emerging vaccine platforms such as mRNA, DNA, viral vector, subunit, and inactivated vaccines based on design rationale, delivery systems, immunogenicity profiles, and global rollouts. At the same time, molecular mechanisms of antiviral drugs acting against viral polymerases, proteases, and entry mechanisms are discussed, and the new challenge of resistance evolution is emphasized. We also highlight recently developed molecular diagnostic tools like CRISPR-based tools, nanopore sequencing, and isothermal amplification technologies that are transforming real-time pathogen diagnosis in veterinary and human medicine. Last, the One Health aspect is introduced through veterinary applications of vaccines to zoonotic spillover prevention and antimicrobial resistance. In conclusion, this review gives a vision-orientated account of molecular strategies that bring together human and animal medicine to combat future pandemics. Our aggregated tables and visualizations are an asset for researchers, clinicians, and policymakers interested in the improvement of epidemic preparedness and cross-species disease surveillance.

Indexed as

Communicable Diseases, EmergingViral VaccinesViral ZoonosesVirus DiseasesZoonosesAnimalsAntiviral AgentsHumansVaccine DevelopmentAntiviral AgentsViral VaccinesAntiviral ResistanceDiagnostic InnovationMolecular VaccinologyOne HealthZoonotic Viruses

Identifiers

PMID41769292
PMCPMC12936593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.